文献速递临床微生物分子诊断质量管理与危急值

脆弱拟杆菌群:鉴定、耐药、分类与临床意义更新

Time for Some Group Therapy: Update on Identification, Antimicrobial Resistance, Taxonomy, and Clinical Significance of the Bacteroides fragilis Group.
PubMed 文献 · J Clin Microbiol · 2022-06-14

脆弱拟杆菌群(BFG)是人体常见菌群,也是临床感染常见厌氧菌,对青霉素耐药率>90%、碳青霉烯类2-20%、甲硝唑0.2-4%。全基因组测序支持BFG重新分类为两个科和多个属,建议临床开展种水平鉴定与药敏试验。

要点

  • BFG对青霉素耐药率>90%,碳青霉烯类2-20%,甲硝唑0.2-4%。
  • 严重BFG感染经验治疗可能不足,应进行药敏试验。
  • 全基因组测序支持BFG分类为两个科、多个属,建议种水平鉴定。

核心结论

  • BFG是临床感染常见厌氧菌,耐药率较高,严重感染需药敏试验指导治疗。
  • 全基因组测序支持BFG分类更新为两个科和多个属,建议临床开展种水平鉴定。

研究设计与样本

  • 综述,检索并总结BFG鉴定、耐药、分类和临床意义相关文献。

主要发现

  • BFG对青霉素耐药率>90%,碳青霉烯类2-20%,甲硝唑0.2-4%。
  • BFG感染可导致不良临床结局。
  • 全基因组测序支持BFG跨越两个科和多个属。
  • 新报道显示BFG耐药谱存在种特异性趋势,鉴定工具分辨率提高支持种水平报告。

关键数值与推荐

  • 青霉素耐药率>90%(BFG)。
  • 碳青霉烯类耐药率2-20%(BFG)。
  • 甲硝唑耐药率0.2-4%(BFG)。
  • 推荐对严重BFG感染进行药敏试验。
  • 建议临床实践中常规报告种水平鉴定结果。

临床怎么用

  • 对严重BFG感染,经验治疗可能不足,应进行药敏试验。
  • 临床微生物实验室应尽量鉴定到种水平并报告。
  • 药敏试验方法包括肉汤微量稀释法、琼脂稀释法、全基因组测序和MALDI-TOF MS。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bacteroides fragilis group (BFG) species are common members of the human microbiota that provide several benefits to healthy hosts, yet BFG are also the most common anaerobes isolated from human infections, including intra-abdominal infections, abscesses, and bloodstream infection. Compared to many other anaerobes associated with disease, members of the BFG are more likely to be resistant to commonly used antimicrobials, including penicillin (>90% resistant), carbapenems (2 to 20% resistant), and metronidazole (0.2 to 4% resistant). As a result, infection with BFG bacteria can be associated with poor clinical outcomes. Here, we discuss the role of BFG in human health and disease, proposed taxonomic reclassifications within the BFG, and updates in methods for species-level identification. The increasing availability of whole-genome sequencing (WGS) supports recent proposals that the BFG now span two families (Bacteroidaceae and "Tannerellaceae") and multiple genera (Bacteroides, Parabacteroides, and Phocaeicola) within the phylum Bacteroidota. While members of the BFG are often reported to "group" rather than "species" level in many clinical settings, new reports of species-specific trends in antimicrobial resistance profiles and improved resolution of identification tools support routine species-level reporting in clinical practice. Empirical therapy may not be adequate for treatment of serious infections with BFG, warranting susceptibility testing for serious infections. We summarize methods for antimicrobial susceptibility testing and resistance prediction for BFG, including broth microdilution, agar dilution, WGS, and matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS). We examine global trends in BFG antimicrobial resistance and review genomics of BFG, revealing insights into rapid activation and dissemination of numerous antimicrobial resistance mechanisms.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Jean S, Wallace MJ, Dantas G, et al. Time for Some Group Therapy: Update on Identification, Antimicrobial Resistance, Taxonomy, and Clinical Significance of the Bacteroides fragilis Group. J Clin Microbiol. 2022. PMID: 35700139. doi:10.1128/jcm.02361-20

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。